Novo Holdings

Novo Holdings functions as the investment and asset management arm for the Novo Nordisk Foundation, recognized as one of the largest enterprise foundations globally. With a strategic focus on generating sustainable long-term returns, the organization maintains controlling ownership stakes in both Novo Nordisk and Novonesis, collectively known as the Novo Group companies. This financial powerhouse has established itself as a significant force in the investment landscape, leveraging its substantial resources to build a diversified portfolio spanning multiple asset classes and investment horizons.

The investment approach at Novo Holdings is comprehensively structured across multiple specialized teams handling different stages of capital deployment. Their life science investments are managed through dedicated divisions including Seeds (early-stage), Venture Capital, Growth, and Principal Investments teams, allowing them to support biotech and pharmaceutical innovations from inception through maturity. This stage-agnostic strategy enables Novo to maintain a continuous presence throughout the development lifecycle of portfolio companies, providing not just capital but also strategic guidance leveraging their deep industry expertise.

Beyond life sciences, Novo Holdings maintains a sophisticated multi-asset investment strategy encompassing public equities, credit instruments, real estate holdings, infrastructure projects, and private equity investments. This diversification strategy helps balance the portfolio's risk profile while optimizing returns across different market conditions. Their investment professionals bring extensive experience from global financial markets, employing rigorous analysis and due diligence processes to identify opportunities with attractive risk-adjusted return potential across geographies and sectors.

In recent years, Novo Holdings has expanded its investment thesis to include Planetary Health Investments, reflecting a forward-thinking approach to addressing interconnected global challenges. This initiative specifically targets innovative solutions at the intersection of human health and environmental sustainability, recognizing that these domains are increasingly inseparable. Through this focused investment vertical, Novo supports companies developing technologies and approaches that simultaneously benefit public health outcomes while addressing critical environmental challenges such as climate change, resource scarcity, and ecosystem preservation. This dual-purpose investment strategy aligns with growing recognition of the need for sustainable development approaches that consider both human and planetary wellbeing.